""

A CLEAR CHOICE With Proven Efficacy

Manage acne, acne scarring, and acne induced PIH*cd

AKLIEF® (triferotene) Cream, 0.005% delivers rapid acne reduction1 while helping prevent and reduce scarring² and improve post-acne hyperpigmentation.³abcd
 

These outcomes are driven by its unique RAR-γ†–selective mechanism, making Aklief the first and only topical retinoid designed to reduce inflammation, normalize skin cell turnover, and modulate skin remodeling.4,5

Acne reduction on face 

  • Significant reduction in facial inflammatory and noninflammatory acne lesions seen by Week 2¹a
  • More than 50% reduction in facial inflammatory lesions by Week 8¹a
  • 66.2% reduction in facial inflammatory lesions by Week 12¹a
Explore Facial Acne Outcomes

Acne reduction on the trunk

  • Effective for acne on chest, shoulders and back1a
  • Significant improvement in truncal acne observed as early as Week 21a
  • 66.4% reduction in trucal lesions by Week 121a
     
Explore Truncal Acne Outcomes

Reduction in acne and acne scarring 

  • Significant reduction in acne and acne scarring, with rapid and visible improvements observed as early as Week 22.2


     
Explore Acne & Scarring Outcomes

Reduction in acne and acne induced PIH

  • Patients saw faster improvement of acne and acne induced PIH when using Aklief cream vs vehicle alone3cd
  • Rapid decrease of PIH severity in acne patients observed over the first 12 weeks of treatment and continued to reduce facial PIH through Week 24.3cd
Explore Acne & PIH Outcomes

Proven across diverse patients and multiple acne outcomes

Aklief Cream has been evaluated in a robust clinical development program involving more than 2,787 patients with moderate-to-severe acne.1,2,3,5 Clinical studies have demonstrated efficacy in clearing facial and truncal acne¹, reducing and preventing acne scars², and improving the appearance of acne-induced post-inflammatory hyperpigmentation (PIH)³d across diverse skin tones and skin types.⁷

Explore Visible Results

*PIH, post-inflammatory hyperpigmentation

†RAR, retinoic acid receptor

a. Studied in acne patients from 9 to 58 years of age with diverse skin types and moderate-to-severe acne. Nodulocystic acne was excluded from the trials.

b. Significant improvement seen as early as Week 1 in the pivotal clinical trials.

c. Secondary to clearing acne.

d. The primary endpoint was the overall disease severity score (ODS). No statistical significance between AKLIEF Cream and vehicle at Week 24 was seen.

 

References

  1. Tan J, Thiboutot D, Popp G, et al. Randomized Phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699.
  2. Schleicher S, et al. Trifarotene reduces risk for atrophic acne scars: Results from a Phase 4 controlled study. Dermatol Ther (Heidelb). 2023;13(12):3085–3096.
  3. Alexis A, et al. Importance of treating acne sequelae in skin of color: 6-month Phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. 2024;63(6):806–815.
  4. Aubert J, et al. Br J Dermatol. 2018;179(2):442–456.
  5. Blume-Peytavi U, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–173.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.